Looking to the two trials on bronzoti, the DPP-1 inhibitors, I think that the Willow and husband trials gave us a number of information and a number of perspectives in the management of our patients with bronchiectasis. Uh, the patients we were enrolled, uh, having at least 2 exacerbations in the previous year. And uh these are clearly one important thing because, you know, you can identify the patient uh to be uh a role in treatment, treated. The uh Willow was a phase two study uh looking to the time to exacerbation and then having a a a number of secondary endpoints. But all the, the first endpoint and all the secondary endpoints have been met. And this was also uh this, the case for the Aspen study, where there's a phase phase 3 study, uh, look to as a primary endpoint to the number of analyzed uh number of exacerbation and then look into time to exacerbation, quality of life, pulmonary function testing, and so on. I think overall the two studies showed us that renzoatib worked very well, reducing exacerbation, reducing severe exacerbation compared to placebo, irrespective to the dose used, and this was quite good results looking particularly on the number. Of exacerbation and quality of life, I think is quite important because reduction in exacerbation improves the quality of life. Reduction in severe exacerbation improves the quality of life and possibly in a larger number of patients also can have an impact on mortality. We will see in the next future. But certainly the main result is that the reduction of exacerbation has been demonstrated in both studies. With a very, a very good consistency in between the two dosages, and we know that the indication for FDA and EMA will be a little bit different. At least we in Italy, we will have probably only the highest dose, but in any case, both doses have been demonstrated to be quite effective. And what is impressive is that all the secondary endpoints were reached, and this means that there is a really broad range of positive effect of revocative, and this clearly leads to To be very positive for the next year for the treatment of our patients where we, as we know it's an orphan disease where we till now don't have any treatment. The other important point is that this was obtained on the top of standard of care. So at the end of the day we, I have patients were on physiotherapy where all the possible treatable traits were controlled, and on this patient, they are adding benzotib leads to a reduction in exacerbation, so this could be very, very important results.
Presenter
